MLANA and melanoma: In resected advanced melanoma patients, a therapeutic combination of PD-1 ICB and a multi-antigen vaccine containing gp100, MART-1, and NY-ESO-1 peptides was well tolerated, led to increases in peptide-specific T cells, and resulted in low relapse rate (145).